Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Obesity drugmaker Novo Nordisk on Wednesday posted first-quarter operating profit above analyst forecasts and cut its ...

Within R&D, Novo Nordisk completed the REDEFINE 2 trial, where CagriSema demonstrated superior weight loss of 15.7% in adults ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

--The company currently guides for 16%-24% sales growth at constant exchange rates and for 19%-27% operating profit growth. "With the continued weak trends in the U.S. continuing into 2Q, we now ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

Semaglutide is marketed under the brand names Wegovy ® (once-weekly semaglutide 2.4 mg injection), Ozempic ® (once-weekly ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Novo Nordisk saw a significant decline as it lost over 55% from its highs in June 2024. Check out the reasons for the decline ...

Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...